Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
27 sept. 2019 09h27 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the...
Resverlogix to Host BETonMACE Webcast and Conference Call
26 sept. 2019 19h04 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be...
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
23 sept. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results...
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
14 août 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris,...
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
15 juil. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, July 15, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone (RVX-208)...
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
08 juil. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s...